CN108314658B - 一种多取代噁唑衍生物的制备方法 - Google Patents

一种多取代噁唑衍生物的制备方法 Download PDF

Info

Publication number
CN108314658B
CN108314658B CN201810326839.2A CN201810326839A CN108314658B CN 108314658 B CN108314658 B CN 108314658B CN 201810326839 A CN201810326839 A CN 201810326839A CN 108314658 B CN108314658 B CN 108314658B
Authority
CN
China
Prior art keywords
oxazole derivatives
phenyl
preparation
reaction
polysubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810326839.2A
Other languages
English (en)
Other versions
CN108314658A (zh
Inventor
文丽荣
王嘉辉
李卫
李明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHENYANG SUNSHINE PHARMACEUTICAL Co.,Ltd.
Original Assignee
Qingdao University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao University of Science and Technology filed Critical Qingdao University of Science and Technology
Priority to CN201810326839.2A priority Critical patent/CN108314658B/zh
Publication of CN108314658A publication Critical patent/CN108314658A/zh
Application granted granted Critical
Publication of CN108314658B publication Critical patent/CN108314658B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Abstract

本发明公开了属于有机合成技术领域的一种多取代噁唑衍生物的制备方法。所述方法为:向反应容器中,先后加入取代N‑苯氧基酰胺,取代苯乙炔基碘鎓盐和碳酸钾,加入溶剂1,2‑二氯乙烷,水浴20℃搅拌至反应4小时完毕后,使用旋转蒸发仪浓缩滤液得到粗产物,粗产物用硅胶柱层析分离得到目标化合物。本发明提供的多取代噁唑衍生物的合成方法具有科学合理,合成方法简单,目标化合物产率较高,产物易于纯化等特点。其反应方程式如下:

Description

一种多取代噁唑衍生物的制备方法
技术领域
本发明属于有机合成技术领域,具体涉及一种多取代噁唑衍生物的制备方法。
背景技术
噁唑衍生物是一类特殊的五元杂环化合物,广泛存在于天然产物和药物中,具有重要的生物活性。比如抗菌活性、抗增殖活性、抗真菌和病毒((a)Chem.Rev.1975,75,389.(b)Chem.Res.Toxicol.2002,15,269.)。
此外,噁唑也是重要的合成中间体和过渡金属催化的重要配体,这就为探索更为多样的反应提供了可能(Org.Lett.2005,7,2325)。
鉴于噁唑衍生物的广泛的生物活性和应用价值,发展一种实用有效地合成噁唑衍生物的新方法具有重要意义。
近年来,制备噁唑衍生物的方法有:
1)2001年,Cacchi课题组发展了一种从炔丙酰胺出发,经过零价钯催化后与碘苯反应,得到了2,5-二取代的噁唑化合物。(Org.Lett.2001,3,2501.)
2)2010年,Hashmi等人建立了一种金催化炔丙酰胺得到甲级噁唑衍生物的方法。(Chem.-Eur.J.2010,16,956.)
3)2015年,Shi课题组发展了一种在金和铁这两种金属的共同作用下,得到噁唑醛化合物的新方法。(J.Am.Chem.Soc.2015,137,8912)
制备噁唑衍生物的上述方法,具有一定的缺点和不足:1)需要用当量的酸或其他脱水剂;2)用到重金属,污染严重。3)原子经济性不好。
发明内容
为了克服上述现有技术的不足,作为对现有噁唑衍生物合成方法的补充,本发明提供了一种多取代噁唑衍生物的制备方法。
一种多取代噁唑衍生物的制备方法,所述噁唑衍生物具有式Ⅰ所示的结构:
R1取代基团选自氟、氯、甲基;R2选自甲基、苯基、取代苯基,取代苯基的取代基团是溴、甲基;R3选自苯基、取代苯基,取代苯基的取代基团是氟、氯、甲基;其特征在于,向反应器中,加入取代N-苯氧基酰胺和取代苯乙炔基碘鎓盐和碱,在溶剂中搅拌反应完毕后,使用旋转蒸发仪浓缩得到粗产物,粗产物使用硅胶柱层析分离得到目标产物,其化学过程见反应式Ⅱ:
所述的取代N-苯氧基酰胺、取代苯乙炔基高碘化合物和碳酸钾的摩尔比值为1.2:1:2。所述溶剂为1,2-二氯乙烷,反应温度为20℃,反应时间为4h。
本发明的有益效果为:本发明提供的多取代噁唑衍生物的合成方法科学合理,提供了一种合成多取代噁唑的新途径,通过本方法得到了具有多种取代基的多取代噁唑衍生物,其特点为:合成方法简单,目标化合物收率较高,产品易于纯化。
附图说明
图1为实施例1制备的化合物3aa的NMR图谱;
图2为实施例5制备的化合物3ea的NMR图谱;
图3为实施例9制备的化合物3ac的NMR图谱;
具体实施方式
下面结合附图和具体的实施例对本发明进一步详细的说明:
下述实施例中所述试验方法,如无特殊说明,均为常规方法;所述试剂和材料,如无特殊说明,均可从商业途径获得。
实施例1
1)噁唑衍生物3aa的制备
向10ml圆底烧瓶中加入N-苯氧基乙酰胺1a(0.36mmol,54.4mg)、2a(0.3mmol,104.4mg)和K2CO3(0.6mmol,82.9mg)。加入1,2-二氯乙烷(2mL),在20℃的水浴中搅拌,反应4小时。反应完毕后,使用旋转蒸发仪除去溶剂得到粗产物,粗产物经柱层析分离(200-300目硅胶)(石油醚/乙酸乙酯=4/1),使用旋转蒸发仪除去溶剂,得到目标产物多取代噁唑衍生物3aa,其收率为90%。
谱图解析数据3aa:
1H NMR(500MHz,DMSO-d6)δ9.87(s,1H),7.49(d,J=7.5Hz,2H),7.35–7.24(m,4H),7.20(t,J=7.3Hz,1H),6.98(d,J=8.2Hz,1H),6.88(t,J=7.5Hz,1H),2.46(s,3H);13C NMR(125MHz,DMSO)δ160.34,156.22,143.04,135.10,132.54,131.62,131.57,128.63,127.57,126.28,119.56,116.62,116.49,40.36,40.20,40.04,39.87,39.71,39.54,39.38,14.01;HRMS(ESI)m/z calcd for C16H14NO2 +[M+H]+252.1025,found 252.1026.
实施例2
用1b代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3ba:
1H NMR(500MHz,DMSO-d6)δ9.89(s,1H),7.47(d,J=7.5Hz,2H),7.30(t,J=7.7Hz,2H),7.23(t,J=7.4Hz,1H),7.15(ddt,J=12.5,9.0,4.3Hz,2H),6.95(dd,J=9.0,4.7Hz,1H),2.47(s,3H);13C NMR(125MHz,DMSO-d6)δ160.66,156.28,154.41,152.57,141.64,135.68,132.29,128.68,127.80,126.41,118.16,117.98,117.69,117.40,117.21,13.99;HRMS(ESI)m/z calcd for C16H13NO2F+[M+H]+270.0930,found 270.0932.
实施例3
用1c代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3ca:
1H NMR(500MHz,DMSO-d6)δ10.17(s,1H),7.45(d,J=7.4Hz,2H),7.38–7.26(m,4H),7.22(t,J=7.3Hz,1H),6.96(d,J=8.9Hz,1H),2.46(s,3H);13C NMR(125MHz,DMSO-d6)δ160.74,155.12,141.37,135.82,132.29,131.15,130.64,128.69,127.83,126.42,122.83,118.32,118.19,40.41,40.24,40.08,39.90,39.74,39.57,39.41,13.97;HRMS(ESI)m/z calcd forC16H13NO2Cl+[M+H]+286.0635,found 286.0638.
实施例4
用1d代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3da:
1H NMR(500MHz,DMSO-d6)δ9.60(s,1H),7.49(d,J=9.5Hz,2H),7.28(t,J=7.6Hz,2H),7.21(d,J=7.7Hz,1H),7.14–7.06(m,2H),6.86(d,J=8.2Hz,1H),2.46(s,3H),2.19(s,3H);13C NMR(125MHz,DMSO-d6)δ160.24,153.89,143.08,143.07,134.96,132.60,132.04,131.59,128.59,128.10,127.51,126.25,116.48,116.19,40.38,40.21,40.04,39.88,39.71,39.54,39.37,20.30,14.02;HRMS(ESI)m/z calcd for C17H16NO2 +[M+H]+266.1181,found 266.1185.
实施例5
用1e代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3ea:
1H NMR(500MHz,DMSO-d6)δ10.01(s,1H),8.07(dd,J=7.5,1.8Hz,2H),7.63(d,J=7.4Hz,2H),7.56(q,J=5.2Hz,3H),7.45–7.32(m,4H),7.28(t,J=7.3Hz,1H),7.04(d,J=8.2Hz,1H),6.95(t,J=7.5Hz,1H);13C NMR(125MHz,DMSO-d6)δ159.91,156.39,143.84,136.74,132.29,131.89,131.75,131.02,129.59,128.73,127.98,127.30,126.55,126.36,119.68,116.75,116.15,40.39,40.22,40.05,39.89,39.72,39.55,39.39;HRMS(ESI)m/zcalcd for C21H16NO2+[M+H]+314.1181,found 314.1182.
实施例6
用1f代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3fa:
1H NMR(500MHz,DMSO-d6)δ10.03(s,1H),8.01(d,J=8.2Hz,2H),7.79(d,J=8.2Hz,2H),7.63(d,J=7.4Hz,2H),7.49–7.22(m,5H),7.05(d,J=8.1Hz,1H),6.97(t,J=7.3Hz,1H);13C NMR(125MHz,DMSO-d6)δ159.09,156.36,144.15,136.92,132.66,132.12,131.96,131.71,128.74,128.28,128.07,126.55,124.50,119.67,116.76,115.95,40.23,40.06,39.90,39.73,39.57,39.41;HRMS(ESI)m/z calcd for C21H15NO2Br+[M+H]+392.0286,found 392.0286.
实施例7
用1g代替实例1中的1a,其他条件同实例1,实验结果见表1。
谱图解析数据3ga:
1H NMR(500MHz,DMSO-d6)δ9.96(s,1H),7.93(d,J=8.1Hz,2H),7.59(d,J=7.4Hz,2H),7.40–7.30(m,6H),7.25(t,J=7.3Hz,1H),7.00(d,J=8.2Hz,1H),6.92(t,J=7.5Hz,1H),2.36(s,3H);13C NMR(125MHz,DMSO-d6)δ160.06,156.37,143.49,140.88,136.58,132.37,131.76,130.14,128.70,127.91,126.52,126.34,124.67,119.65,116.72,116.23,40.39,40.23,40.06,39.90,39.73,39.57,39.40,21.47;HRMS(ESI)m/z calcd forC22H18NO2 +[M+H]+328.1338,found 328.1335.
实施例8
用2b代替实例1中的2a,其他条件同实例1,实验结果见表1。
谱图解析数据3ab:
1H NMR(500MHz,DMSO-d6)δ9.89(s,1H),7.56–7.43(m,2H),7.29(dd,J=19.8,7.5Hz,2H),7.12(t,J=8.7Hz,2H),6.96(d,J=8.1Hz,1H),6.88(t,J=7.3Hz,1H),2.45(s,3H);13C NMR(125MHz,DMSO-d6)δ162.69,160.74,160.40,156.12,142.77,134.32,131.54,129.13,128.24,119.61,116.69,116.28,115.61,115.44,40.44,40.28,40.11,39.95,39.78,39.62,39.46,13.96;HRMS(ESI)m/z calcd for C16H13NO2F+[M+H]+270.0930,found270.0936.
实施例9
用2c代替实例1中的2a,其他条件同实例1,实验结果见表1。
谱图解析数据3ac:
1H NMR(500MHz,DMSO-d6)δ9.91(s,1H),7.47(d,J=8.6Hz,2H),7.36(d,J=8.6Hz,2H),7.34–7.27(m,2H),6.96(d,J=8.1Hz,1H),6.89(t,J=7.4Hz,1H),2.47(s,3H);13C NMR(125MHz,DMSO-d6)δ160.58,155.99,143.35,134.11,132.09,131.67,131.52,131.41,128.68,127.97,119.65,116.68,116.11,40.37,40.20,40.03,39.87,39.70,39.53,39.37,13.98;HRMS(ESI)m/z calcd for C16H13NO2Cl+[M+H]+286.0635,found 286.0637.
实施例10
用2d代替实例1中的2a,其他条件同实例1,实验结果见表1。
谱图解析数据3ad:
1H NMR(500MHz,DMSO-d6)δ9.81(s,1H),7.36(d,J=7.8Hz,2H),7.33–7.20(m,2H),7.07(d,J=7.8Hz,2H),6.96(d,J=8.1Hz,1H),6.86(t,J=7.3Hz,1H),2.44(s,3H),2.23(s,3H);13C NMR(125MHz,DMSO-d6)δ160.20,156.18,142.54,136.82,135.16,131.58,131.42,129.78,129.20,126.27,119.51,116.60,40.39,40.23,40.06,39.89,39.73,39.56,39.39,21.16,14.01;HRMS(ESI)m/z calcd for C17H16NO2+[M+H]+266.1181,found266.1183。
表1

Claims (3)

1.一种多取代噁唑衍生物的制备方法,所述噁唑衍生物具有式Ⅰ所示的结构:
式Ⅰ中,R1取代基团选自氟、氯、甲基;R2取代基团选自甲基、苯基、取代苯基,取代苯基的取代基团是溴、甲基;R3取代基团选自苯基、取代苯基,取代苯基的取代基团是氟、氯、甲基;其特征在于,向反应器中,加入取代N-苯氧基酰胺和取代苯乙炔基碘鎓盐和碱,在溶剂中搅拌反应完毕后,使用旋转蒸发仪浓缩得到粗产物,粗产物用硅胶柱层析分离得到式Ⅰ所示的多取代噁唑衍生物;该制备方法用式Ⅱ表示:
2.根据权利要求1所述的制备方法,其特征在于:取代N-苯氧基酰胺、取代苯乙炔基碘鎓盐和碱的摩尔比值为1.2:1:2。
3.按照权利要求1所述的制备方法,其特征在于:溶剂为1,2-二氯乙烷,反应温度为20℃,反应时间为4小时。
CN201810326839.2A 2018-04-12 2018-04-12 一种多取代噁唑衍生物的制备方法 Active CN108314658B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810326839.2A CN108314658B (zh) 2018-04-12 2018-04-12 一种多取代噁唑衍生物的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810326839.2A CN108314658B (zh) 2018-04-12 2018-04-12 一种多取代噁唑衍生物的制备方法

Publications (2)

Publication Number Publication Date
CN108314658A CN108314658A (zh) 2018-07-24
CN108314658B true CN108314658B (zh) 2019-09-06

Family

ID=62897358

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810326839.2A Active CN108314658B (zh) 2018-04-12 2018-04-12 一种多取代噁唑衍生物的制备方法

Country Status (1)

Country Link
CN (1) CN108314658B (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108947995B (zh) * 2018-09-17 2021-03-16 青岛科技大学 一种多取代噁二嗪衍生物的制备方法
CN109851599B (zh) * 2019-03-19 2022-03-08 青岛科技大学 一种2-氨基苯并呋喃化合物的制备方法
CN110156710B (zh) * 2019-04-30 2022-10-28 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种多取代噁唑类化合物的制备方法
CN115536605B (zh) * 2022-08-22 2023-12-15 广东工业大学 一种硼试剂参与的多取代噁唑化合物的制备方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106749077B (zh) * 2017-03-27 2019-05-21 广西师范大学 一种合成噁唑化合物的方法

Also Published As

Publication number Publication date
CN108314658A (zh) 2018-07-24

Similar Documents

Publication Publication Date Title
CN108314658B (zh) 一种多取代噁唑衍生物的制备方法
Liu et al. A highly efficient and eco-friendly method for the synthesis of 1, 3-indandione ring-fused 3-oxindoles bearing two contiguous quaternary stereocenters via an aldol reaction in aqueous media
CN108794357B (zh) 一种n-二氟甲基腙类化合物及其合成方法
CN111875612B (zh) 色满酮拼接吡咯螺环氧化吲哚骨架与三氟甲基类化合物及其制备方法及应用
CN112661764B (zh) 一种四氢呋喃并吲哚类化合物及其制备方法和应用
CN110156710A (zh) 一种多取代噁唑类化合物的制备方法
CN113651788B (zh) 一种3-胺烷基色酮化合物及其制备方法
JP5665041B2 (ja) ヨードニウム化合物、その製造方法、及び官能基化スピロ環状化合物とその製造方法
CN114369045B (zh) 一种含氟烷硫基取代的烯烃衍生物及其合成方法
CN110511197B (zh) 一种n-呋喃酮基芳基磺酰腙类化合物及其合成方法和应用
CN110240572B (zh) 一种反式-1,1-环丙烷二羧酸酯的合成方法
CN108610306B (zh) 一种2h-1,4-噻嗪-3(4h)-酮衍生物的合成方法
CN112574225A (zh) 一种四氢呋喃并二氢喹啉类化合物及其制备方法和应用
CN109384753B (zh) 一种2-苯基-3-甲基苯并呋喃类化合物的合成方法
CN111100085A (zh) 一种3-芳基-2H-苯并[β][1,4]苯并恶嗪-2-酮化合物的制备方法
CN108947995A (zh) 一种多取代噁二嗪衍生物的制备方法
CN104910090B (zh) 二氢异噁唑类化合物及其合成方法
CN113200902B (zh) 一种多取代吡咯衍生物及其制备方法
CN112745275B (zh) 1,3,4-恶二唑杂环化合物的合成方法
CN115160331B (zh) 一种氧化吲哚螺烯丙基取代色满骨架及其制备方法
CN114634427B (zh) 一种含螺环的茚并多环类化合物的制备方法
CN114181182B (zh) 一种多取代的4h-吡喃类化合物的合成方法
CN110041285B (zh) 一种2,4,5-三取代噁唑类化合物的制备方法
CN111138346B (zh) 2-乙基-4,6-二取代吡啶类化合物及其制备方法
CN108822058B (zh) 一种苯并噻嗪类化合物的制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210617

Address after: 224500 No.50, industrial branch road, private industrial park, Tongyu Town, Binhai County, Yancheng City, Jiangsu Province

Patentee after: Binhai Yuzhuo technology consulting studio

Address before: No. 53, Zhengzhou Road, North District, Qingdao, Shandong

Patentee before: Qingdao University Of Science And Technology

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20210630

Address after: 110027 No.1-3, No.10 Road, Shenyang Economic and Technological Development Zone, Liaoning Province

Patentee after: SHENYANG SUNSHINE PHARMACEUTICAL Co.,Ltd.

Address before: 224500 No.50, industrial branch road, private industrial park, Tongyu Town, Binhai County, Yancheng City, Jiangsu Province

Patentee before: Binhai Yuzhuo technology consulting studio